The clinically approved antiviral drug sofosbuvir impairs Brazilian zika virus replication
Caroline Q. Sacramento, Gabrielle R. de Melo, Natasha Rocha, Lucas Villas Boas Hoelz, Milene Mesquita, Caroline S. de Freitas, Natalia Fintelman-Rodrigues, Andressa Marttorelli, Andre C. Ferreira, Giselle Barbosa-Lima, Monica M. Bastos, Eduardo de Mello Volotao, Diogo A. Tschoeke, Luciana Leomil, Fernando A. Bozza, , Thiago Souza
This study shows sofosbuvir inhibits Brazilian ZIKV replication by targeting RNA polymerase, suggesting it as a potential antiviral for ZIKV.
bioRxiv · Jul 6, 2016Microbiology